Replies to post #677 on Revance Therapeutics Inc (RVNC)

[DewDiligence]

Re: Hugel

The “other” possible entrant that post is referring to is presumably Hugel’s Botulax, which is approved in Korea and Taiwan (http://www.theinvestor.co.kr/view.php?ud=20181204000586 ).

The US development rights to Botulax are owned by a JV of Hugel and an Austrian company called Choma-Pharma (http://www.theinvestor.co.kr/view.php?ud=20181204000586 ); however, it’s unclear whether—or when—this JV might make a serious attempt to bring Botulax to the US market.